Down 6% in a month: Is it time to buy CSL shares?

Is now a good time to invest? Let's see what Bell Potter is saying.

| More on:
A man looking at his laptop and thinking.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares have been under pressure in September.

So much so, the biotechnology giant's shares have fallen over 6% since this time last month. As a comparison, the ASX 200 index is up approximately 1% over the same period.

This has been driven by softer than expected guidance for FY 2025, which spooked investors. Though, it is worth remembering that CSL is often conservative with its guidance, so don't be surprised if it is upgraded as the year progresses.

With that in mind, is now a good time to snap up the company's shares? Let's see what one leading broker is saying.

Is it time to buy CSL shares?

According to a recent note out of Bell Potter, its analysts have named CSL on their Australian equities panel again this month.

It notes that this "panel of favoured Australian equities offer attractive risk-adjusted returns over the long term." The broker considers "the current macro-economic backdrop and investment environment, focusing on quality companies with proven track records, capable management and competitive advantages."

CSL ticks all of the these boxes in September and features on the panel. Commenting on the company, the broker said:

CSL is one of the world's largest global plasma fractionators. The plasmaproducts themselves have proven excellent medical products, with wide application, and deliver therapeutic outcomes difficult to achieve by other means. The company has a proven track record of deploying capital effectively and generating high returns over the past 25 years.

Its analysts believe that a buying opportunity has now opened up for investors with CSL shares. It adds:

CSL presents an attractive buying opportunity as we anticipate the start of a margin recovery phase for CSL, driving above-market earnings growth over the next few years. CSL trades at a 12-month forward PE of ~31x, representing a discount to its 5 year average of ~35x. Furthermore, the company will continue to deleverage the balance sheet over the next few years. Given the company's proven quality and growth prospects, we believe significant upside remains.

Buy rating

The note reveals that Bell Potter has a buy rating and $316.50 price target on the company's shares right now.

Based on the current CSL share price of $290.04, this implies potential upside of 9.1% for investors over the next 12 months.

In addition, a modest 1.5% dividend yield is expected by the broker in FY 2025. This lifts the total potential return on offer with its shares to approximately 10.5%.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »